SL
SLDB.US Solid Biosciences LLC
- Market cap
- USD 695M
- P/E
- -
- P/B
- 2.12x
- ROE
- -64.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SLDB.US undervalued?
Graham numberThe Graham number of Solid Biosciences LLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Solid Biosciences LLC fundamental analysis
No fundamental analysis for Solid Biosciences LLC yet.
Solid Biosciences LLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilat…
Full company profileSolid Biosciences LLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Solid Biosciences LLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.34M | 13.6M | 8.09M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -56.0K | -448K | -1.57M | -2.82M | -3.92M | 13.6M | 8.09M | -2.58M | -2.46M | -1.64M | - |
| Operating Income | -25.6M | -54.9M | -75.7M | -119M | -86.5M | -72.3M | -106M | -104M | -130M | -179M | -230M |
| EBITDA | -25.5M | -54.4M | -74.1M | -116M | -84.4M | -69.2M | -96.9M | -93.4M | -122M | -173M | -219M |
| Net Income | -21.5M | -52.1M | -74.8M | -117M | -88.3M | -72.2M | -86.0M | -96.0M | -125M | -174M | -221M |
| EPS | -17 | -24 | -34 | -44 | -26 | -10 | -10 | -4.83 | -3.06 | -1.99 | -1.46 |
| Balance Sheet | |||||||||||
| Total Assets | 40.6M | 76.2M | 140M | 103M | 171M | 232M | 260M | 165M | 189M | 233M | 390M |
| Total Liabilities | 78.5M | 135M | 14.4M | 23.4M | 39.1M | 24.2M | 48.6M | 38.5M | 51.4M | 52.5M | 47.8M |
| Shareholders' Equity | -84.4M | -59.3M | 125M | 80.0M | 132M | 208M | 212M | 126M | 137M | 180M | 342M |
| Cash & Short-term Investments | 37.7M | 69.1M | 122M | 83.5M | 155M | 208M | 214M | 124M | 149M | 188M | 349M |
| Total Debt | - | - | 1.89M | 7.07M | 5.15M | 2.06M | 28.5M | 26.3M | 24.2M | 21.2M | 19.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -20.1M | -43.2M | -70.2M | -92.7M | -56.6M | -77.8M | -98.0M | -94.2M | -100M | -156M | -194M |
| Capital Expenditure | 392K | 2.28M | 7.78M | 4.39M | 899K | 1.28M | 3.02M | 1.52M | 654K | 1.15M | 1.08M |
| Free Cash Flow | -20.5M | -45.5M | -78.0M | -97.1M | -57.5M | -79.0M | -101M | -95.7M | -101M | -157M | -195M |
| Ratios | |||||||||||
| ROE | - | - | -59.8% | -146.4% | -66.8% | -34.7% | -40.6% | -75.9% | -90.9% | -96.8% | -64.5% |
| ROA | -53.0% | -68.4% | -53.6% | -113.3% | -51.6% | -31.1% | -33.0% | -58.2% | -66.1% | -75.0% | -56.6% |
| Net Profit Margin | - | - | - | - | -2,647.4% | -530.0% | -1,062.3% | - | - | - | - |
| Debt to Equity | - | - | 0.02x | 0.09x | 0.04x | 0.01x | 0.13x | 0.21x | 0.18x | 0.12x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Solid Biosciences LLC dividends
Solid Biosciences LLC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Oct 28, 2022.
Who owns Solid Biosciences LLC
- Insiders 0.66%
- Institutions 99.34%
- Public & others 0.00%
- Shares outstanding 112M
- Free float 69.2M
Top funds holding SLDB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.15M | 2.82% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 2.72M | 2.44% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 2.61M | 2.34% | 0.00% | Aug 2026 |
| iShares Russell 2000 ETF | 1.91M | 1.72% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.88M | 1.68% | +2.69% | Oct 2026 |
| Columbia Small Cap Growth Inst | 1.76M | 1.58% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 1.47M | 1.32% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 865K | 0.77% | +0.21% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 678K | 0.61% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 668K | 0.60% | -0.19% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 530K | 0.47% | +0.27% | Oct 2026 |
| Fidelity Series Small Cap Core | 480K | 0.43% | -4.04% | Aug 2026 |
| Columbia Small Cap Value Discv A | 456K | 0.41% | +0.73% | Sep 2026 |
| Vanguard Russell 2000 ETF | 438K | 0.39% | -2.98% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 404K | 0.36% | -31.82% | Sep 2026 |
| Fidelity Small Cap Discovery | 361K | 0.32% | +6.04% | Aug 2026 |
| iShares Russell 2000 Value ETF | 357K | 0.32% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 345K | 0.31% | -0.38% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 336K | 0.30% | +0.24% | Oct 2026 |
| Dimensional US Small Cap ETF | 319K | 0.29% | 0.00% | Oct 2026 |
Top institutions holding SLDB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 12.0M | 10.78% | +28.87% | Jun 2026 |
| Perceptive Advisors LLC | 11.9M | 10.67% | 0.00% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 9.81M | 8.79% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 7.69M | 6.89% | 0.00% | Jun 2026 |
| BlackRock Inc | 6.93M | 6.21% | +39.85% | Jun 2026 |
| FMR Inc | 6.88M | 6.16% | +90.66% | Jun 2026 |
| Armistice Capital, LLC | 4.28M | 3.83% | +33.69% | Jun 2026 |
| State Street Corp | 4.18M | 3.74% | +270.98% | Jun 2026 |
| Jupiter Topco LLC | 4.04M | 3.62% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.01M | 3.59% | +49.92% | Jun 2026 |
| RTW INVESTMENTS, LLC | 3.89M | 3.49% | 0.00% | Jun 2026 |
| Deep Track Capital, LP | 3.57M | 3.19% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 3.44M | 3.08% | +56.90% | Jun 2026 |
| Citadel Advisors Llc | 2.82M | 2.52% | +8.41% | Jun 2026 |
| Alyeska Investment Group, L.P. | 2.28M | 2.04% | +0.02% | Jun 2026 |
| Ameriprise Financial Inc | 2.23M | 1.99% | -8.74% | Jun 2026 |
| Vestal Point Capital LP | 2.16M | 1.94% | -56.80% | Jun 2026 |
| Redmile Group, LLC | 1.95M | 1.75% | -3.14% | Jun 2026 |
| Geode Capital Management, LLC | 1.94M | 1.74% | +49.76% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.60M | 1.44% | +71.34% | Jun 2026 |
Solid Biosciences LLC company profile
- Company name
- Solid Biosciences LLC
- Ticker
- SLDB.US
- Exchange
- USA Stocks
- Listed since
- Jan 26, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 121
- Fiscal year end
- December
- Address
- 500 Rutherford Avenue, Charlestown, MA, United States, 02129
- Phone
- 617 337 4680
- Website
- solidbio.com
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Solid Biosciences LLC management
10- Mr. Ian F. Smith A.C.A., C.P.A.Executive Chair · born 1966
- Mr. Alexander G. CumboPresident, CEO & Director · born 1971
- Mr. Ilan GanotCo-founder, Strategic Advisor to the CEO & Director · born 1974
- Mr. David Tyronne Howton Jr., J.D.COO & Secretary · born 1972
- Dr. Gabriel Brooks M.D.Chief Medical Officer · born 1977
- Ms. Annie GanotCo-Founder & VP of Patient Advocacy
- Mr. Kevin Tan C.F.A.CFO & Treasurer · born 1978
- Mr. Paul HerzichChief Technology Officer · born 1978
- Ms. Nicole AndersonSenior Director of Investor Relations & Corporate Communications
- Dr. Jessie Hanrahan Ph.D.Chief Regulatory & Preclinical Operations Officer · born 1976